Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies01:28

Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies

Peptic ulcer disease (PUD) presents with diverse symptoms depending on the location and severity of the ulcer. Clinical manifestations of peptic ulcer include dull pain and a burning sensation in the mid-epigastric region.
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High relapse rates after budesonide in microscopic colitis: a large retrospective analysis revealing the need for advanced therapies.

Acta gastro-enterologica Belgica·2026
Same author

Outcomes of autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease: a single-center retrospective case series.

Acta gastro-enterologica Belgica·2026
Same author

Multi-stakeholder Delphi consensus on future care for inflammatory bowel disease in Belgium.

Acta gastro-enterologica Belgica·2026
Same author

Estimated benefits and willingness of remote monitoring in IBD patients in remission under maintenance therapy: results of a questionnaire in a tertiary referral centre.

Acta gastro-enterologica Belgica·2026
Same author

Using Natural Isotopes for the Environmental Tracking of a Controlled Landfill Site for Non-Hazardous Waste in Liguria, Italy.

International journal of environmental research and public health·2025
Same author

Treatment patterns and outcomes of patients with complex Crohn's perianal fistula in five European countries: the PREFACE study.

Acta gastro-enterologica Belgica·2025

Related Experiment Video

Updated: May 23, 2026

Establishment of a Murine Pulp Exposure Model with a Novel Mouth-Gag for Pulpitis Research
05:16

Establishment of a Murine Pulp Exposure Model with a Novel Mouth-Gag for Pulpitis Research

Published on: October 27, 2023

Prostaglandin E2 to diagnose between reversible and irreversible pulpitis.

M Petrini1, M Ferrante, L Ciavarelli

  • 1Department of Oral Sciences, Nano and Biotechnology, University G. d'Annunzio, Chieti, Italy.

International Journal of Immunopathology and Pharmacology
|April 18, 2012
PubMed
Summary

Prostaglandin E2 (PGE2) levels correlate with dental pulp inflammation. Higher PGE2 indicates reversible pulpitis, while NSAIDs decrease levels, aiding in distinguishing pulpitis stages.

More Related Videos

Inducing Apical Periodontitis in Mice
10:26

Inducing Apical Periodontitis in Mice

Published on: August 6, 2019

Related Experiment Videos

Last Updated: May 23, 2026

Establishment of a Murine Pulp Exposure Model with a Novel Mouth-Gag for Pulpitis Research
05:16

Establishment of a Murine Pulp Exposure Model with a Novel Mouth-Gag for Pulpitis Research

Published on: October 27, 2023

Inducing Apical Periodontitis in Mice
10:26

Inducing Apical Periodontitis in Mice

Published on: August 6, 2019

Area of Science:

  • Biomedical Science
  • Oral Biology
  • Inflammation Research

Background:

  • Dental pulp inflammation is a common clinical issue.
  • Prostaglandin E2 (PGE2) is a key inflammatory mediator.
  • Accurate diagnosis of pulpitis stages is clinically significant.

Purpose of the Study:

  • To investigate the correlation between PGE2 concentration and the histological grade of inflammation in human dental pulp.
  • To determine if PGE2 levels can differentiate between reversible and irreversible pulpitis.
  • To assess the effect of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) on PGE2 levels in dental pulp.

Main Methods:

  • Histological analysis of 25 human dental pulp samples.
  • Radioimmunoassay (RIA) for quantifying PGE2 concentration.
  • Comparison of PGE2 levels in healthy, reversible pulpitis, and irreversible pulpitis groups.

Main Results:

  • PGE2 concentration was significantly higher in reversible pulpitis compared to healthy dental pulps.
  • PGE2 levels were also elevated in irreversible pulpitis but showed a clear decrease with NSAID use.
  • Histological analysis confirmed a correlation between PGE2 levels and the grade of pulp inflammation.

Conclusions:

  • PGE2 concentration serves as a reliable biomarker for assessing the severity of dental pulp inflammation.
  • PGE2 levels can aid clinicians in distinguishing between reversible and irreversible pulpitis.
  • NSAIDs demonstrably reduce PGE2 levels, suggesting a therapeutic role in managing pulpitis.